3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of LifeAbnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Polyuria, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorderRecruitingPhase 32026-08-25NCT05373264
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKINeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 22026-01-21NCT05601973
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA StudyArterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, peripheral arterial disease, peripheral vascular disease, vascular disorderActive, not recruitingNot applicable2025-09-23NCT04776434